These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27480578)

  • 1. Optimized design and analysis of preclinical intervention studies in vivo.
    Laajala TD; Jumppanen M; Huhtaniemi R; Fey V; Kaur A; Knuuttila M; Aho E; Oksala R; Westermarck J; Mäkelä S; Poutanen M; Aittokallio T
    Sci Rep; 2016 Aug; 6():30723. PubMed ID: 27480578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Software for animal randomization: A tool for increasing the reproducibility of science.
    da Fonseca Cardoso LM; da Silva Ferreira NC; de Araripe Lopes Correa M; da Silva SA; Alves LA
    Lab Anim; 2024 Apr; 58(2):164-169. PubMed ID: 37898111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The usefulness of matched pair randomization for medical practice-based research.
    McClatchey MW; Cohen SJ; Reed FM
    Fam Pract Res J; 1992 Sep; 12(3):235-43. PubMed ID: 1414427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An original patient-derived xenograft of prostate cancer with cyst formation.
    Yoshikawa T; Kobori G; Goto T; Akamatsu S; Terada N; Kobayashi T; Tanaka Y; Jung G; Kamba T; Ogawa O; Inoue T
    Prostate; 2016 Aug; 76(11):994-1003. PubMed ID: 27098584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mean comparisons and power calculations to ensure reproducibility in preclinical drug discovery.
    Novick S; Zhang T
    Stat Med; 2021 Mar; 40(6):1414-1428. PubMed ID: 33300171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing prostate cancer patient derived xenografts: lessons learned from older studies.
    Russell PJ; Russell P; Rudduck C; Tse BW; Williams ED; Raghavan D
    Prostate; 2015 May; 75(6):628-36. PubMed ID: 25560784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
    Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
    Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simulation study of the validity and efficiency of design-adaptive allocation to two groups in the regression situation.
    Aickin M
    Int J Biostat; 2009 May; 5(1):Article 19. PubMed ID: 20224630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
    Yamamoto Y; De Velasco MA; Kura Y; Nozawa M; Hatanaka Y; Oki T; Ozeki T; Shimizu N; Minami T; Yoshimura K; Yoshikawa K; Nishio K; Uemura H
    J Transl Med; 2015 May; 13():150. PubMed ID: 25953027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The power and promise of RNA-seq in ecology and evolution.
    Todd EV; Black MA; Gemmell NJ
    Mol Ecol; 2016 Mar; 25(6):1224-41. PubMed ID: 26756714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration.
    Frost GI; Lustgarten J; Dudouet B; Nyberg L; Hartley-Asp B; Borgström P
    Microvasc Res; 2005 Jan; 69(1-2):1-9. PubMed ID: 15797254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal sample sizes for the design of reliability studies: power consideration.
    Shieh G
    Behav Res Methods; 2014 Sep; 46(3):772-85. PubMed ID: 24197712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The direct assignment option as a modular design component: an example for the setting of two predefined subgroups.
    An MW; Lu X; Sargent DJ; Mandrekar SJ
    Comput Math Methods Med; 2015; 2015():210817. PubMed ID: 25649690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental Design and Power Calculation for RNA-seq Experiments.
    Wu Z; Wu H
    Methods Mol Biol; 2016; 1418():379-90. PubMed ID: 27008024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of key genes associated with prostate cancer using RNA-seq data.
    Wu J; Feng F; Yang D; Yu S; Liu J; Gao Z
    Int J Biol Markers; 2014 Mar; 29(1):e86-92. PubMed ID: 24366848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data.
    Shedden K; Chen W; Kuick R; Ghosh D; Macdonald J; Cho KR; Giordano TJ; Gruber SB; Fearon ER; Taylor JM; Hanash S
    BMC Bioinformatics; 2005 Feb; 6():26. PubMed ID: 15705192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four simple ways to increase power without increasing the sample size.
    Lazic SE
    Lab Anim; 2018 Dec; 52(6):621-629. PubMed ID: 29629616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental design, power and sample size for animal reproduction experiments.
    Chapman PL; Seidel GE
    Reprod Fertil Dev; 2008; 20(1):33-44. PubMed ID: 18154696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation.
    Malik M; Hnatkova K; Batchvarov V; Gang Y; Smetana P; Camm AJ
    Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.